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Background: Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill
several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex
genetic network, culminating in apoptosis. Normal lymphoblasts and many lymphoid malignancies are sensitive to
GC-driven apoptosis. Resistance to GCs can be a significant clinical problem, however, and correlates with resistance
to several other major chemotherapeutic agents.
Methods: We analyzed the effect of treatment with the cytosine analogue 5 aza-2’ deoxycytidine (AZA) on GC
resistance in two acute lymphoblastic leukemia (T or pre-T ALL) cell lines- CEM and Molt-4- and a (B-cell) myeloma
cell line, RPMI 8226. Methods employed included tissue culture, flow cytometry, and assays for clonogenicity,
cytosine extension, immunochemical identification of proteins, and gene transactivation. High throughput DNA
sequencing was used to confirm DNA methylation status.
Conclusions: Treatment of these cells with AZA resulted in altered DNA methylation and restored GC-evoked
apoptosis in all 3 cell lines. In CEM cells the altered epigenetic state resulted in site-specific phosphorylation of the
GR, increased GR potency, and GC-driven induction of the GR from promoters that lie in CpG islands. In RPMI 8226
cells, expression of relevant coregulators of GR function was altered. Activation of p38 mitogen-activated protein
kinase (MAPK), which is central to a feed-forward mechanism of site-specific GR phosphorylation and ultimately,
apoptosis, occurred in all 3 cell lines. These data show that in certain malignant hematologic B- and T-cell types,
epigenetically controlled GC resistance can be reversed by cell exposure to a compound that causes DNA
demethylation. The results encourage studies of application to in vivo systems, looking towards eventual clinical
applications.
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Malignant cells may preempt the natural epigenetic
mechanism of cytosine methylation to alter expression
of genes so as to escape anti-cancer therapy. Epigenetics
includes chemical modifications of DNA, and/or chro-
matin structural proteins such as nuclear histones, with
resulting effects on gene transcription. Methylation of
cytosine nucleotides in genomic CpG islands, often lo-
cated in proximal promoter regions, is known to nega-
tively affect transcription of certain genes. In cancer,
disruption of the normal DNA methylation patterns can
result in an aberrant epigenetic state with substantial
consequences, such as repression of tumor suppressors,
leaving cells susceptible to oncogenetic transformation
[1-7]. The cellular epigenetic state can affect other fac-
tors as well, e. g. cell cycle arrest through p21WAF1 and
activation of the p38 MAPK signal transduction pathway
[8]. Expression of nuclear hormone receptors, including
the GR, also has been shown to be affected at the epi-
genetic level [9-11]. Repression of gene expression based
on DNA methylation can be reversed by analogs of cyto-
sine such as 5 aza-2’ deoxycytidine (AZA), which incorp-
orate into the genome of actively dividing cells and can
render the cytosine nucleotide sites which they replace
incapable of methylation [1,3,6,8,12]. Clinically, AZA
alone shows promising activity against acute myeloid
leukemia and myelodysplastic syndromes [1,3,12,13].
GC-driven apoptosis of several types of leukemic cells
provides the rationale for use of GCs in many chemo-
therapy regimens. This GC action requires activation of
the GR (nr3c1), a ligand-dependent transcription factor,
with subsequent regulation of a complex gene network
[14], one affected strongly by other signal transduction
pathways, including those involving protein kinase A
(PKA) and the mitogen-activated protein kinases
(MAPKs) [15-18]. However, GC resistance can be a clin-
ical problem, often associated with resistance to other
drugs and poor overall prognosis. Examination of clinical
leukemia specimens has revealed that resistance in vivo
is occasionally due to mutation within the GR gene or
loss of GR, but too often it is found that though the GR
is present and unmutated, the receptor is ineffectual in
causing apoptosis [19-22].
In 1983, it was discovered that in the mouse spontan-
eous thymic lymphoma cell line SAK8, the DNA methy-
lation state could affect GC-sensitivity [23,24]. We
subsequently tested AZA on dexamethasone (Dex)-re-
sistant human leukemic CEM cells, producing a few
sub-clones of apparent revertants to sensitivity [25].
Based on this preliminary work, we have now tested the
hypothesis that apoptotic sensitivity to GCs in certain
human hematologic malignancies is controlled via the
epigenetic state of the genomic DNA by examining the
ability of AZA treatment to restore GC sensitivity tocells from three hematological malignancies: two types
of acute lymphoblastic leukemia (ALL), CEM clone C1-
15 (preT or early T-cell), and uncloned MOLT-4 (T-
cell), and a resistant myeloma cell line, RPMI 8226. We
confirm that treatment with AZA can convert GC-
resistant CEM cells to GC-sensitive and show that this
effect extends as well to the other cell lines, represent-
ing both T- and B-lineage malignancies. After AZA
treatment, some clones appear stably converted to GC-
sensitive. We show that in this conversion, several cell
line-specific effects relevant to GR function occur.
These include altered GR expression from transcrip-
tional start sites at specific untranslated exons located
in CpG islands, hypomethylation, expression and sensi-
tivity to GC of coregulatory factors that affect GR ac-
tions, and in the MAPK pathway, alterations known to
be favorable for GR phosphorylation and action. Our
present study connects the cellular DNA methylation
state with the networked, hormone-driven apoptotic ac-
tions of the GR. The results encourage research at the
in vivo level, and since AZA is already in clinical use for
certain hematologic malignancies, our results open the
possibility of extending use of demethylating com-
pounds to revert GC resistant malignancies to GC
sensitive.
Results
Brief exposure to the genomic DNA demethylating agent
AZA restores the GC-dependent apoptotic response in
each of three cell lines
We evaluated the contribution of the epigenetic state to
GC resistance in three commonly used model systems of
human lymphoid hematologic malignancies: 1) CEM-
C1-15, a GC-resistant clone of the pediatric ALL cell
line CCRF-CEM; 2) Molt-4, an uncloned T-cell derived
pediatric ALL cell line; and 3) RPMI 8226, an uncloned
myeloma line (B-cell lineage). The cells of each system
contain functional GR; yet each is highly resistant to
GC-evoked apoptosis [26,27]. Initially, we treated each
system with AZA for 24 h; then added Dex and followed
the cultures over time. There was significant near-term
restoration of sensitivity to Dex-driven apoptosis in each
system. Thus, the % reduction in live cells treated with
AZA 24 h followed by Dex for 72 h, compared to 72 h
Dex only, was 87% for MOLT-4 (n = 4, each in tripli-
cate), 74% for RPMI 8226 (n = 2, in triplicate) and 86%
for CEM C1-15 (n = 3, in triplicate). Since AZA incorp-
oration into replicating DNA results in multiple pheno-
types, possibly not entirely random [28,29], one could
not expect every cell in the treated populations to convert
to Dex sensitivity; so it is striking that in repeated experi-
ments, such treatment always resulted in a near-term shift
to sensitivity in a significant proportion of the population.
In all three systems, phase-contrast visualization of the cells
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tosis: cell shrinkage, nuclear condensation, karyorrhexis,
and eventually, cell lysis. To estimate how many cells of
each system were stably affected, we cloned each popula-
tion after exposure to AZA or DMSO vehicle for 48 hours.
About 1 month later, in a screening process, many clones
were evaluated individually for Dex sensitivity. Because in
some lymphoid cell systems Dex can arrest cell growth
without causing apoptosis, we evaluated both repression of
growth (total reduction in viable cells, and intact, yet apop-
totic cells remaining at the end of the treatments. For this
relatively high-throughput screen, we used trypan blue dye
exclusion as a working definition of viability. Figures 1, 2Figure 1 AZA treatment of Dex-resistant C1-15 restores GC-dependent
or DMSO for 48 hours were cloned by serial dilution to single cells and allowed
exposed to 1 μM Dex or vehicle for 96 h and characterized for viable ( exclude
% growth repression (total reduction in viable cells, x-axis) and % apoptotic cells
of revertant clone CEM-IV B9. B. Overall methylation of DNA from untreated CE
assay- (DPMs of incorporated 3H dCTP per μg of genomic DNA). Error bars = 1
naturally Dex-sensitive CEM-C7-14 (dashed line, closed diamonds), Dex-resistant
(spontaneous revertant from C1-15, closed squares), and CEM IV B9 (demethylat
hours for numbers of viable cells. - Shown is the average percentage - of viable
were treated with vehicle (control) or 1 μM Dex for 96 hours and evaluated by
cells, extensive cell death and secondary, post apoptotic lysis allowed modelling
results (avg. of 2 expts), see Table 1.and 3 show results for CEM, MOLT-4 and RPMI 8226
cells, respectively. Panels 1A, 2A, and 3A show the data
evaluating many individual clones as soon as clone out-
growth was sufficient for the assays. Each dot represents
one clone, with % repression of growth on the x-axis, and %
apoptotic (trypan blue positive) but still intact cells on the
y-axis. While this analysis allows a rough estimate of the
separation between growth retardation and ongoing apop-
tosis, it can underestimate the total quantity of cells lysed
before the evaluations, since these are not “seen” by the in-
strument used. Nevertheless, the data in Figures 1A-3A
show that in early clones from resistant cells pre-treated
only with DMSO (open symbols), Dex caused varyingsensitivity to CEM clones. A. CEM-C1-15 cells - treated with 100 nM AZA
to regrow. 105 DMSO and 94 AZA-treated outgrown clones were then
trypan blue) and apoptotic (intact, trypan blue positive) cells. Plotted are
within the remaining intact cell population (y-axis). B-D, Studies
M-C1-15 cells vs - clone CEM-IV B9, by cytosine extension
SD, n = 5. p = 0.0003. C. GC (Dex) sensitivity. Triplicate cultures of
CEM-C1-15 (closed circles), and two - revertant clones: CEM-C1-6
ed revertant, open circles) were treated with 1 μM Dex and followed for 96
cells. Error bars = 1 SD -. D. Flow cytometry. The four - clones -of panel C
flow cytometry. Data in graphs representative of biological n = 2. For IV B9
of <20,000 events. All four panels are at same scale. Cell cycle
Figure 2 Treatment with AZA restores sensitivity to GCs in Molt-4 cells. A. Molt-4 cells treated for 48 hours with DMSO or 100 nM AZA were
cloned by serial dilution to single cells and viable cell populations were allowed to regrow. % growth repression and residual apoptotic cells after 96
hours of 1 μM Dex treatment for control (49 clones, open diamonds) or AZA (49 clones, closed squares) are plotted. Upon further culture, the
Dex-sensitivity of these clones proved to be unstable; therefore in B-D, experiments were performed on the MOLT-4 mass culture. B. DNA
methylation of uncloned Molt-4 cells treated with DMSO vehicle or 100 nM AZA for 48 h. Data show DPMs of incorporated 3H dCTP per μg of gen-
omic DNA. Error bars = 1 SD, n = 5. p = 0.001, DMSO vs. AZA C. Timing of response to Dex. Molt-4 cells were treated in triplicate with vehicle
(control, closed squares), 1 μM Dex (open squares), 100 nM AZA (closed triangles), or 100 nM AZA for 24 hours before adding 1 μM Dex (open
triangles). Average percentage of 3 independent replicates for cell culture viability following the addition of Dex. Sensitive clone CEM-C7-14 (C7-14,
dashed line, closed triangles, data from Figure 1C) included for comparison. Error bars = 1 SD. D. Flow cytometry of uncloned MOLT-4 cells treated
with AZA, Dex or AZA followed by Dex. Cells were treated as in C. with evaluation by PI staining and flow cytometry 72 hours after Dex. Each
histogram (all histograms are same scale) results from the collection of 20,000 “events” where possible. n = 1. Extensive cell loss caused lower number
of “events” in lower right hand histogram. Cytometric evaluations, Table 1.
Miller et al. Cancer Cell International 2014, 14:35 Page 4 of 17
http://www.cancerci.com/content/14/1/35degrees of growth repression with relatively few apoptotic
cells to be found after 96 h. In contrast, in the clones de-
rived from AZA treated cultures (closed symbols) Dex
treatment often caused growth arrest plus a significant
percentage of apoptotic cells at 96 h, suggesting ongoing
apoptosis. Extensive growth arrest and Dex-dependent
apoptosis generally were correlated in cells from all
three lines pre-treated with AZA, consistent with our
previous observations on the cell-cycle effects of Dex on
sensitive CEM cells [30]. We conclude that the AZA ef-
fect is widespread, due to effects on many individual
cells, and that the acute sensitization to Dex may some-
times persist.CEM cells (Figure 1). Visual and Vi-cell evaluation of
the CEM-C1-15 cell clones indicated that no clone in
this experiment treated with DMSO alone reverted to
GC-mediated apoptotic sensitivity. On the other hand,
many clones from AZA-treated C1-15 cells showed high
Dex sensitivity. Clone IV B9 (extreme upper right,
Figure 1A) derived after AZA, showed a striking rever-
sion to Dex-sensitivity, and it remained phenotypically
stable over 4 months in continuous culture and after re-
peated freeze-thawing; therefore it was taken for further
evaluation. Cytosine extension assay results (Figure 1B)
indicated that clone IV B9 DNA was 4-fold hypomethy-
lated relative to CEM-C1-15 cells. High throughput
Figure 3 AZA restores GC-dependent sensitivity to clones of multiple myeloma cells derived from the resistant RPMI 8226 parent. A.
RPMI 8226 cells were treated with 100 nM AZA or an equivalent volume of DMSO for 48 hours. Cells were then dilution cloned to single cells,
and viable cell populations were allowed to regrow. Percentages of growth repression vs. apoptosis after 96 hours of 1 μM Dex treatment for
control (50 clones, open diamonds) or AZA (47 clones, closed squares) are plotted as in Figure 1A. Revertant clone RPMI-II E6 is indicated. B. The
methylation states of DNA for uncloned RPMI 8226 cells without AZA treatment and of revertant clone RPMI-II E6 were evaluated by cytosine
extension assay. Data are presented as DPMs of incorporated 3H dCTP per μg of genomic DNA. Error bars = 1 standard deviation from the mean.
n = 5 for RPMI-II E6 and 6 for RPMI 8226. p = 0.08, RPMI 8226 vs. RPMI-II E6. C. RPMI 8226 and II E6 cells were treated in triplicate with ethanol
(control, closed diamond, closed triangles) or 1 μM Dex (Dex, open diamonds, open triangles) for 96 hours with final evaluation using Trypan blue
exclusion to estimate vialble cells. Shown is the average percentage of 3 independent replicates for cells able to exclude the dye (% culture
viability). Error bars = 1 standard deviation from the mean. D. RPMI 8228 and clone II E6 were treated with ethanol vehicle (control) or 1 μM Dex
for 96 hours, then stained with PI and evaluated by flow cytometry. Each histogram represents the results from the collection of 20,000 events
where possible. n = 3. Note that Y-axis scales are all identical; in the lower two panels, loss of cells due to lysis reduced the number of countable
“events” in the cytometer. Also, see Table 1.
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tion in DNA in all autosomes, relative to the resistant
CEM C1-15 cells. From CEM C1-15, CEM C7-14 and
revertant IV B9 cells, non-methylated and methylated
DNA were separated and sequenced (Methods). The
average coverages for non-overlapping 5,000 bp windows
were calculated across all chromosomes, examining all
DNA and also only unique gene locations. Coverage
comparisons of C1-15 and C7-14 sequences enriched for
methylated DNA showed that many C1-15 sequencescontained regions- both repeat sequences and unique
sequences- with high methylation that were not found in
the C7-14 data. Similarly, a plot of sensitive revertant IV
B9 against its resistant parent C1-15 revealed loss of
methylation at many sites in IV B9.
Comparisons of Dex-sensitivity between clone IV B9,
natively sensitive CEM-C7-14, the spontaneous revertant
CEM-C1-6 (described in [27]), and the resistant parental
clone CEM-C1-15, showed IV B9 to be most Dex-
responsive in both loss of viable cells and in rapidity of
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to lower concentrations of Dex than other sensitive
clones, shown by the leftward shift of the dose response
curve and a greater lytic response to Dex (Figure 1C,
1D, Table 1). Flow-cytometric evaluation of propidium
iodide (PI) stained DNA in cells reinforced these data
(Figure 1D, Table 1).
MOLT-4 cells. Of the 3 cell systems, MOLT-4 showed
the greatest acute response as a mass culture (Figure 2
and data cited in text). Clearly, there also is a shift to
more GC response in the demethylated clones from
MOLT-4 cells (Figure 2A). Upon extended culture, the
Dex-sensitive phenotype of these clones proved to be
unstable, however. The data in Figure 2B-2D therefore
evaluate the Molt-4 mass culture following acute treat-
ment with AZA and Dex. Test of the DNA after 48
hours of exposure to AZA confirmed demethylation
(Figure 2B). Treatment of the cells with AZA for 24
hours followed by the addition of Dex resulted in a
marked loss of cell viability over time (Figure 2C). After
treatment with AZA only, there was a 20-25% reduction
in viable cells (% culture viability, y-axis) Dex alone re-
duced viability by only about 5%. AZA followed by Dex,
however, reduced viability in this experiment by 50%.
These results support the conclusion that an epigenetic
state is responsible, at least in part, for the GC resistance of
many Molt-4 cells, though the AZA/Dex synergy could in-
clude additional mechanisms. Flow cytometry also indi-
cated that the mass culture of MOLT-4 cells treated with
AZA had undergone some cell loss (Figure 2D lower left
panel and Table 1) However, there was a drastic reductionTable 1 Cell cycle analysis, Figures 1, 2 and 3D
Cell type Treatment %G1









Figure 2D, MOLT-4 (uncloned) Control 58.82
Dex 62.85
AZA 58.02
AZA + Dex 73.64
Figure 3D, RPMI (uncloned) Control 61.71
Dex 59.88
RPMI clone II E6 Control 56.02
Dex 51.31of intact cells after treatment with AZA followed by Dex,
and an increase of cell debris, coupled with a reduction in
total viable cells, resulting in a reduction in cells available
for evaluation by flow cytometry. (Figure 2D, lower right
panel. The scale for all histograms in Figure 2D is identical.)
The cytometric evaluation also showed a shift of the re-
sidual population into G1, typical of the apoptotic effect of
Dex in many lymphoid cell systems, e.g. CEM [30]. Since
phase-contrast microscopy had shown these cells to go
through the morphologic phases of apoptosis, we conclude
that at this 96 hr time point, many cells in the culture had
gone on to secondary necrosis/lysis.
RPMI cells (Figure 3) The mass culture of RPMI 8226
myeloma cells also became sensitive to Dex-induced lysis
after treatment with AZA. Many outgrown clones showed
significant growth arrest and ongoing apoptosis (Figure 3A).
The most sensitive clone (II E6) was stable in phenotype
and was kept for further analysis. In this clone, cytosine ex-
tension assay did not detect a statistically significant shift in
total DNA methylation (Figure 3B). Exposure of clone II E6
to Dex revealed a significant loss of viable cells by 48 hr,
comparable to CEM clone IV B9, and faster than CEM
clones C1-6 and C7-14 (Compare Figures 1C and 3C). Flow
cytometry also showed that under control conditions, clone
II E6 sustained an ongoing low level of apoptosis, presum-
ably a result of the earlier AZA treatment (lower left panel,
Figure 3D and Table 1) After 96 hr in Dex, clone II E6
showed a near complete loss of viable cells, and only a few
remaining cells had sub-diploid DNA content (Figure 3D
Note, the scale of the Y-axis in all panels of 3D is identical,
and see Table 1).%G2 % S % A % Deb
6.125 36.27 00.035 00.845
29.45 21.19 34.18 25.92
4.18 44.83 00.075 1.715
7.31 28.44 00.02 25.43
8.705 39.6 00.005 00.88
9.355 37,8 2.07 2.055
5.975 35.6 00.09 1.405
5.435 35.95 58.855 18.75
8.57 32.62 00.03 5.83
8.14 29.0 00.12 2.94
10.00 31.8 00.66 21.3
6.64 19.72 00.00 34.91
11.73 26.46 00.00 2.32
9.31 30.81 6.40 2.87
11.51 32.47 6.72 11.30
42.6 6.09 1.5 46.58
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and Dex
Because the % apoptosis appeared low in the method
used for evaluation of RPMI 8226 cells, we performed a
clonogenicity assay, a classic measure of cellular malig-
nant potential- the ability to restore a population from
single cells. To test the effect of altered methylation on
the clonogenicity of RPMI 8226 cells, we treated with
vehicle alone, Dex, AZA, or AZA plus Dex, and subse-
quently cloned each sample by serial dilution in fresh
medium in multi-well plates. After seeding on average,
1000, 100, 10, and 1 cells per well, two weeks were
allowed for growth, and viable cells were counted by
Trypan blue exclusion assay. All the wells seeded initially
at 1000 were too overgrown to count and were not eval-
uated further. Dex treatment alone had, if any, slight
positive effects on cloning efficiency and the ability of
the cells to repopulate from any starting density. Alone,
AZA reduced the number of cells grown from 100 , 10,
or single cell wells but failed to block clone formation.
Combination of AZA and Dex resulted in a complete
loss of clonogenicity for single cells and a marked reduc-
tion in growth in the 10-cell wells (Table 2). Thus, com-
bination treatment with AZA and Dex significantly
compromised the clonogenicity/oncologic potential of
RPMI 8226 cells.
The data of Figures 1, 2 and 3 and Tables 1 and 2
demonstrate that in three cell systems, AZA treatment
restores sensitivity to Dex-induced cell death. In an ini-
tial exploration of mechanisms, we examined the effects
of the AZA treatment on some known important ele-
ments in Dex-dependent apoptotic pathways.
GC-stimulated events involving p38 MAPK , a
feed-forward stimulator of GR action, are important for
glucocorticoid-dependent apoptosis in all 3 cell systems
GC-stimulated p38 MAPK activation plays a major role
in the glucocorticoid-dependent apoptotic mechanism in
a variety of malignant lymphoid cell lines, including
CEM, Molt-4 and RPMI 8226 [17,18,27,31-33]. Elevated
p38 relative to JNK and ERK MAPKs favors an apoptoticTable 2 Clonogenicity of RPMI 8226 cells
Starting cells/well 10
Cloning efficiency




AZA + Dex 75
Clonogenicity of RPMI 8226 cells is reduced by treatment with AZA followed by De
hours before addition of ethanol vehicle (control) or 1 μM Dex for an additional 96
single cells in cloning medium. Cells from independent wells for each treatment we
are cloning efficiency, range and sum of viable cells from all wells seeded with 10 oresponse in a variety of malignant lymphoid cells [32].
The GR is phosphorylated by p38 (and other kinases) at
ser 211, which enhances GR transcriptional and apop-
totic activities [17,18,27,33]. Comparisons of the resist-
ant parent CEM-C1-15, its demethylated clone IV B9,
and the spontaneous revertant CEM-C1-6 revealed a
strong increase in phosphorylated (i.e., activated) p38
MAPK in response to Dex stimulus in both IV B9 and
C1-6 cells, and at best, a very slight increase in C1-15
cells. (Figure 4). Levels of total p38 MAPK protein
remained unchanged, consistent with earlier reports
[17,18]. To test the importance of the GC-stimulated
p38 activity for apoptosis, the demethylated, stable rever-
tants CEM IV B9 and RPMI II E6 were treated with the
p38 inhibitor SB203580 for 1 hour before the addition of
1 μM Dex, and viable cells were enumerated 48 h later.
With the SB added to block p38, there was statistically
significant protection from Dex-driven apoptosis for the
SB-treated cells in both systems, with an increase in
total viable cells after Dex (Figure 5). In the SB-treated
cultures, there was also a statistically significant increase
in the % of viable cells in the cell populations still
present at the end of the experiment. This fraction in-
creased from 33% (Dex only) to 62% (SB + Dex) (p =
0.001) for IV B9 cells, and in II E6 cells, from 48% to
68% (p = 0.003). These results are consistent with partial
inhibition of the Dex-induced ongoing apoptosis. Also,
in Molt-4 cells, the uncloned, mass culture system,
treated acutely with AZA, followed by Dex with or with-
out SB, modest, but statistically significant protection
was seen when the p38 blocker was added: AZA alone
reduced culture viability by 25%; AZA followed by Dex
reduced viability by 60%. There was a statistically signifi-
cant 30% gain in viable cells when SB was added to the
Dex + AZA treatment: p = 0.02, n = 3. This partial in-
hibition of cell death in all three systems is as expected,
since ser211 phosphorylation of the GR enhances, but is
not essential for GR actions. The data above identify
p38 as one possible AZA-sensitive node shared by all
three cell systems in the known complex of pathways ini-
tiated by Dex that lead to apoptotic cell death. GR is1 10 1
Viable cells/well
(×10-5) ± SD
50 6.0 ± 1.3 0.15 ± 0.3
75 6.9 ± 1.3 1.2 ± 1.5
50 0.7 ± 0.6 0.06 ± 0,1
0 0.14 ± 0.1 0
x. RPMI 8226 cells were incubated with 100 nM AZA or DMSO vehicle for 40
hours. Cells were then serially diluted to initial staring densities of 100, 10, or
re counted using a Trypan blue exclusion assay 2 weeks after cloning. Shown
r single cells for each treatment. Data in bold emphasize the AZA+Dex effect.
Figure 4 Dex-stimulated p38 MAPK phosphorylation/activation
is increased in revertant CEM clones. CEM-C1-15 (C1-15 resistant),
CEM-C1-6 (C1-6 spontaneous sensitive revertant), and CEM-IV B9 (IV
B9 hypomethylated sensitive revertant) were treated with ethanol
vehicle (C) or 1 μM Dex (D) for 16 hours after which time whole cell
lysates were analyzed using immunoblots with an antibody specific
to phospho-p38 protein. Membranes were subsequently re-probed
with an antibody recognizing total p38 protein. Illustrated is a
representative blot of 4 independent experiments for IV B9 cells, all
with similar results. C1-15 and C1-6 are included for comparison
n = 4. We have previously published detailed analysis of the MAPK
pathway in these CEM clones [17].
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further examined aspects of GR function. Both sufficient
quantity and activity of the GR are known to be essential
for it to drive lymphoid cell apoptosis.
GR functions are enhanced by differing mechanisms in
CEM and RPMI 8226 cells
The p38 effects suggest one node of common action, highly
relevant to GR activity, in the AZA-reverted cells of all
three systems. However, considering the complex networks
of interacting cellular signal systems, it is not surprising
that additional, cell system-specific, non-overlapping effects
influencing GR levels and activity were found. In the CEM
cell system we observed: enhanced GR function, induction
of GR protein and GR phosphorylation, and use of GR al-
ternative promoters. Figure 6A shows that Dex induced GR
protein in naturally sensitive clone C7-14 cells, in C1-6, the
spontaneous revertant to sensitivity from C1-15 cells, and
in the revertant clone IV-B9, obtained from C1-15 cells
after AZA treatment. Dex did not induce GR protein in
C1-15 cells. In C1-15 cells, there was lower basal GR
ser211 phosphorylation and only weak induction, compared
to the other three, Dex-sensitive cell clones. GR-driven
transcriptional activity was consistent with these results.
Cells were transfected with a GRE-driven luciferase re-
porter construct (Methods) and treated with Dex. Therewas highly increased GR transcriptional activity in both
revertant clones C1-6 and IV B9 compared to C1-15
(Figure 6B). Revertant IV B9 showed at least 2-fold elevated
activity over that of the spontaneous revertant C1-6, con-
sistent with the cell death and GC dose-response data in
Figure 1. It appears that the phosphorylation state of the
GR at S211, total GR protein levels, and transactivation po-
tential can be controlled by epigenetic mechanisms in this
system.
Considering the Dex-dependent auto-induction of GR
in these cells, and the correlation between such induc-
tion and apoptosis that has been reported [34], we evalu-
ated the promoter-specific, basal and Dex-driven
expression of the GR in revertant clone IV B9, compared
to other relevant CEM clones. There are 11 untranslated
exon 1 sequences at the 5’ end of the human GR [35],
arising from specific human GR gene promoters. The
promoter (s) for transcripts 1A and 1I are ~25 kbp up-
stream of exon 2, the first peptide coding exon and do
not lie in a CpG island. The remaining promoters are
proximal, located in the GC rich ~5 kb directly up-
stream from Exon 2 [36]. Hypothesizing that expression
from 1A would be unaffected by AZA treatment, while
transcription from one or more of the proximal pro-
moters would be increased, we measured transcripts
from GR exon 1A3, a T-cell selective promoter, and from
exons 1D and 1C, two of the GR’s principal promoters
in the proximal CpG-rich zone. Though transcription
from promoter 1A3 is strongly induced in CEM C7 cells,
this promoter is neither induced nor even expressed well
in spontaneously resistant CEM clones ICR 27, C1-15,
or in sensitive IV B9 cells. Dex-dependent induction of
transcription did not occur from GR promoters 1C and
1D in resistant C1-15 cells, or in a spontaneously resist-
ant CEM clone, ICR 27. This induction was seen,
however, in the Dex-sensitive C1-15 revertant IV B9
(Figure 7). Limited pyrosequencing experiments could
not confirm altered methylation of the proximal GR pro-
moter. Pyrosequencing of a few short regions of the GR
proximal promoter region showed a tendency for greater
methylation at one or two positions in CEM C1-15 cells
as compared to C7-14 cells (data not shown); however.
pyrosequencing of the full 5000 bp promoter was be-
yond the resources available for this study. It will require
further experiments in the future to clarify whether the
GR promoter methylation state directly accounts for the
shift in promoter usage or whether this is an effect sec-
ondary to alterations elsewhere in the genome.
RPMI 8226 myeloma cells: The GC-sensitive revertant II E6
has altered expression of several genes known to affect
GR-driven transcription
We also compared expression from three GR promoters in
Dex resistant RPMI 8226 cells and their stably sensitive
Figure 5 Pharmacological block of p38 MAPK partially inhibits Dex-dependent cell death in CEM and RPMI clones converted to
Dex-sensitive by AZA treatment. CEM IV B9 and RPMI II E6 cells were diluted to a starting density of 1×105 viable cells/ml, pre-treated for 1 hr
with ethanol/DMSO vehicle (control) or 1 μg/ml p38 inhibitor SB203580 (SB) for CEM cells or 2 μg/ml SB for RPMI cells, and subsequently exposed
to 1 μM Dex alone (Dex) or the combination of SB plus Dex (SB + Dex) for an additional 48 hours. Viable cells were counted using an automated
cell counter. Depicted are the average results and standard deviations from 3 independent experiments each consisting of triplicate replicates for
each treatment. Paired t-tests were performed on viable cell numbers and culture viability for (Dex) vs. (SB + Dex). n = 3.
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nil, whereas there clearly was transcription from 1D and 1C
(Figure 7). None of the promoters was induced by Dex in
these cells. However, other mechanisms known to bolster
GR actions were altered, viz. the expression levels and GC
inducibility of the genes for 3 of 5 coregulatory proteins
known to affect GC actions in lymphoid cells [37-39]. Two,
c-Myb and PGC-1a (PGC-1 alpha); act as GR coactivators;
two as corepressors- PU.1 and Tel. Spi-B, the fifth coregula-
tor, seems to interact with GR function, but without a
clearly defined role as yet. None of these showed a clear
pattern that seemed relevant to the CEM revertant (data
not shown), but in the RPMI 8226 cell system, three of the
five were altered so as to enhance GR activity (Figure 8).
Similar basal levels of coactivator c-Myb were found in
RPMI 8226 cells and its sensitive revertant II E6, but ex-
pression was significantly reduced by Dex only in the resist-
ant 8226 cells (Figure 8 right hand bar graphs and inset).
Coactivator PGC-1a also showed similar basal levels in par-
ent and revertant but was strongly induced by Dex in the
sensitive revertant. Corepressor PU.1 did not respond to
Dex, but its level in the sensitive revertant cells was only
about 1% of that in the resistant RPMI 8226 cells. Tel and
Sp1B levels did not correlate with cellular response to
Dex. Interestingly, the regulation of coactivators andcorepressors plays a role in GR action in the pre-B-ALL
697 cell line [38,39]. Thus, in two cell lines in the B-cell
lineage (RPMI 8226 and 697) the regulation of coactivators
and corepressors is important for GC action. In sum, ex-
pression levels and/or Dex regulation of three genes coregu-
latory for GR actions are altered in the Dex-sensitive RPMI
8226 revertant clone in a manner consistent with restoration
of Dex sensitivity through enhanced GR actions.
Discussion
The central finding of the research reported here is that
treatment of three different lymphoid cell lines with
AZA converted the cells from glucocorticoid-resistant to
glucocorticoid-sensitive. The data show that the GC
Dex, given to each resistant cell system soon after AZA,
caused the death of the large majority of cells in the cul-
tures (Data in Results text and Figures 1, 2 and 3). Con-
sequent important issues are, what is the nature of the
cell death and by what mechanisms is it achieved? As to
the nature of the cell death, both the knowledge that
GCs cause lymphoid cell apoptosis and our data herein
suggest that at least the major death pathway in the
AZA, then Dex-treated cells is indeed apoptosis. The
original discovery of apoptosis was made by histopath-
ology [40,41], and indeed, lymphoid cells are one of the
Figure 6 GR site-specific phosphorylation, auto-induction, and potency in Dex-sensitive and –resistant CEM cells. A. GR ser211
phosphorylation and auto-induction. Naturally Dex-sensitive CEM-C7-14 (C7-14), Dex-resistant CEM-C1-15 (C1-15), and two resistant-to-sensitive
revertant clones; CEM-C1-6 (spontaneous revertant, C1-6), and CEM-IV B9 (demethylated revertant, IV B9) were treated in triplicate for 16 hours
with 100 nM Dex (D) or an equivalent volume of ethanol vehicle (C). Cell lysates were then analyzed for phospho-GR S211, total GR, and actin by
immunoblot. Depicted is a representative blot from 3 independent samples done, all with nearly identical results. n = 3. The data shown are from
a single gel, with irrelevant sections removed, for clarity. B. Dex/GR-dependent transcriptional activity. CEM; C1-15, C1-6, and IV B9 cells were
transfected by electroporation with a GRE- dependent luciferase reporter plasmid. Cells were then divided into triplicate replicates and exposed
to either ethanol vehicle (control) or 1 μM Dex for 24 hours after which time extracts were made and luciferase activity analyzed. A representative
experiment is shown of average RLUs normalized to μg of protein in the cellular lysate. Error bars = 1 standard deviation from the mean. Total
biological replicates, n = 2 for C1-15; 5 for C1-6; and 7 for IV B9.
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lowing the recommendations of a large panel of cell
death experts [42], we employed several methods for
evaluating the process- phase contrast microscopy, dye
exclusion, cell shrinkage, and cell cycle analysis- and the
results all point to apoptosis. It may be useful in theFigure 7 Levels of transcription from three important GR untranslate
bottom, GR exons 1A3, 1D, and 1C, expressed in relative fluorescence units
and Methods. The cell line or clone being tested is indicated along the absfuture for ourselves or others to examine additional ele-
ments of apoptosis pathways, of interest to particular
labs.
As to mechanism, the first question is whether altered
DNA methylation is involved. AZA is well-known to
cause reversal of DNA methylation, but the drug cand first exons. Shown are expression levels of transcripts from, top to
(RFU). RNA was quantified using real-time PCR as outlined in Materials
cissa. White bars, treatment with ethanol vehicle; black bars, with Dex.
Figure 8 Expression and regulation of three modulators of GR actions in IIE6, a Dex-sensitive revertant clone from RPMI 8226 cells.
RNA was quantified using real-time PCR as described in d Methods. Shown are the RNA expression levels, before and after Dex treatment, for GR
CoActivators PGC-1a and c-Myb, and the GR CoRepressor PU.1. The inset shows the c-Myb data on an expanded ordinate.
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reason for the restoration to GC sensitivity is altered ex-
pression of genes suppressed by DNA methylation in the
resistant cells, but we cannot rule out the possibility that
some of the restored sensitivity in the short-term is due
to a combination of GC and other AZA effects. These
seem much less likely in long-term revertant cell clones.
In our previous work, comparisons of gene expression
between Dex-sensitive clone CEM-C7-14, Dex-resistant
CEM-C1-15, and the spontaneous resistant-to-sensitive
revertant CEM-C1-6 [27] had suggested that GC-
resistance in CEM cells could be due to altered regula-
tion of large gene networks, a result consistent with
epigenetic control. That is, the extent and pattern of
gene expression in the resistant cells and their sister sen-
sitive cells seemed too broadly different to be due to
mutation of a single gene [27]. Also, our previous pre-
liminary results on the role of DNA methylation in regu-
lating GC-driven apoptosis supported this interpretation
[25]. Consequently, we tested the hypothesis that DNA
methylation of hematological cells could result in loss of
the GC-sensitive phenotype. We treated with AZA to
try to alter the methylation state of 3 cell systems from
different GR-positive, GC-resistant human hematological
malignancies: acute lymphoblastic leukemias Molt-4 (T-
cell), and CEM clone C1-15 (CD4+/CD8+) and the mul-
tiple myeloma (B-cell) line RPMI 8226. (CEM cells have
been designated as either T or pre-T, because they ex-
press surface antigens for both CD4 and CD8, with CD4
predominating quantitatively). Exposure of these B- and
T-lineage lines to AZA results in sensitization of their
mass cultures to Dex-evoked apoptosis, measured byDex-dependent: reduction of viable cells, increased
apoptotic, still intact cells, followed by eventual cell lysis,
and by loss of clonogenicity. We therefore conclude that
most of the cell death seen in the revertant cells is apop-
totic, given the known pro-apoptotic effects of GCs in
lymphoid cells. Total cell DNA methylation was reduced
in the CEM and MOLT-4 cells, but not in the revertant
RPMI clone. Of course, a reduction in overall methyla-
tion is by no means necessary for demethylation at crit-
ical sites to have taken place. Considering that these
cells had gone through many divisions, and the known
demethylating effect of AZA, we conclude that our data
best support the interpretation that apoptotic sensitivity
to GCs in cells from certain lymphoid malignancies can
be controlled by the epigenetic state of the DNA, as our
previous work suggested. We note that epigenetic con-
trol of GC sensitivity at the histone methylation level
has also been reported [19,43]. The importance of epi-
genetic regulation in hematologic malignancies is well
documented, and efforts are being made to to manipu-
late such regulation in vivo [44-51]. Therapy with AZA-
like drugs directed at myelodisplastic syndrome and
AML has given promising results.
As to the mechanisms responsible for the switch to
GC sensitivity, and considering the complex regulatory
networks that control cell health and death and the
widespread alterations in DNA methylation, no doubt
multiple systems will have been affected. We therefore
made choices as to initial studies of mechanism. Because
the reversal of phenotype proved to be unstable in
MOLT-4 clones, we limited experiments to comparing
the effects of AZA, Dex and AZA followed by Dex on
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limits detailed studies of the detailed pathway mecha-
nisms, due to population heterogeneity, it does allow
examination of the effects of each treatment on the sys-
tem. The data show that AZA alone had an acute toxic
effect, Dex alone had little, and the sequential combin-
ation was much more effective in causing cell death.
Stable clones could be obtained from the CEM and
RPMI cells. We elected to pick the most clearly sensitive
of these for more detailed work-up. While one cannot
expect to discover the mechanisms that occur in every
cell or in vivo from such studies, one can hope to find
pathways of importance. Such an approach has proven
valuable innumerable times in the history of science. As
a first, obvious system to investigate, we explored the
GR and several systems that control its actions in AZA-
treated, stable clones from the CEM and RPMI cells.
The known apoptotic effects of GCs in lymphoid cells
require adequate levels of functional GR. We document
several processes that enhance the activity of the GR, in
a cell-line specific manner. In the stably sensitized clone
of CEM cells, we noted restoration of several relevant
GR properties to levels found in GC-sensitive cells:
transcription from important GR promoter sites; GC-
mediated GR induction; and site-specific phosphoryl-
ation of the GR, coupled with an increase in its
transcription-factor potency.
In the RPMI 8226 system, reversion to GC sensitivity
did not correlate with increased GR autoinduction or
quantity. Instead, it correlated with alterations in expres-
sion of GR co-regulators c-Myb, PGC-1a and PU.1 in
ways that, according to published reports of their actions
[38,39,52], should enhance GR activity. Detailed follow-
up of this result will require experiments beyond the
scope of this paper.
Common to all three model cell systems was activation
of p38 MAPK; a kinase that phosphorylates and thus ac-
tivates the GR and is important for GC-driven apoptosis
of several types of malignant lymphoid cells [32]. We
showed that the balance between MAP kinases JNK,
ERK and p38 is one determinant of GC sensitivity [17].
This relationship was shown to be important for GC
sensitivity in 8 unrelated hematologic cell lines [32]. We
hope that these initial findings as to mechanism will lead
to experiments in other lymphoid systems, and that the
results herein will have applicability beyond the cell lines
we tested.
Our results may have potential for eventual clinical
relevance. GCs are used widely in the treatment of
lymphoid malignancies, due to GC-dependent apoptosis
of the malignant cells. But resistance can occur, and re-
sistance to GC often correlates with resistance to other
chemotherapeutic drugs. Though simple loss of GR has
been documented in lymphoblasts from late-stageresistant ALL, and from some lymphomas, this mechan-
ism does not seem to explain the majority of clinical re-
sistance to GCs [20,21,53]. That the GR is required for
GC-driven apoptosis, however, seems quite clear. The
GR is one hub of a complex set of interactive networks
that include at least: c-myc, the MAPKs, PKA, poly-
amines, and redox pathways [31,32,40,54-58]. Thus it is
encouraging that despite this complexity, treatment with
AZA resulted in sensitization to GC-induced apoptosis
of 3 differing lymphoid cell lines. Thus, the data pre-
sented herein provide encouragement for additional
studies aimed at eventually translating DNA demethyla-
tion to clinical use in lymphoid malignancies, as a means
of producing/enhancing sensitivity to GC.
Conclusions
1. Short-term treatment with AZA produced acute- and
in some clones, prolonged sensitivity to GC-driven
apoptosis in 3 lines of malignant lymphoid cells
(2 T cell or pre-T and one of B cell lineage).
2. One nodal function seen to be altered in all three
systems was the activation of p38 MAPK, a known
GR-driven forward feedback system important for
eventual lymphoid cell apoptosis.
3. Further mechanisms were cell-line specific and
included alteration in use of GR promoters,
GC-driven induction of the receptor, and altered
regulation of cofactors that modulate GR function.
4. Given the successful use of DNA demethylating
agents in vivo for the treatment of certain
malignancies, these results encourage further trials




Unless stated otherwise all chemicals were purchased
from Sigma-Aldrich (St. Louis, MO).
Cell culture and treatment
CEM cell clones were derived from the original cell line
CEM-CCRF, which was developed from cells of a
pediatric patient with T-cell ALL. CEM-C1-15 is a Dex-
resistant sub-clone obtained without selective pressure
from its parental resistant clone, CEM-C1. CEM-C1-6 is
a spontaneous revertant to sensitive from CEM-C1 [27].
Clones CEM-IV B9 and RPMI II E6 were chosen from a
subpopulation of CEM-C1-15 or RPMI 8226 cells
treated with AZA. CEM-C7-14 is a subclone of CEM-
C7; both are naturally Dex-sensitive. Molt-4 and RPMI
8226 cells were from the American Type Tissue Collec-
tion (ATCC, Manassas, VA). CEM cells were grown in
RPMI 1640 (Cellgro, Mediatech Inc. Herndon, VA)
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Biologicals, Lawrenceville, GA). Both Molt-4 and RPMI
8226 cells were propagated in RPMI 1640 supplemented
with 10% FBS, 10 mM Hepes buffer (Cellgro), and
1 mM sodium pyruvate. All cells were grown in a tissue
culture incubator in a humidified atmosphere at 37°C,
95% air / 5% CO2 and subcultured regularly to ensure
logarithmic growth. To evaluate Dex sensitivity, cells
were treated with either ethanol vehicle (control) or con-
centrations of Dex ranging from 1 nM to 4 μM. For ex-
periments examining the contribution of p38 MAPK,
cells were pre-treated for 1 hour with DMSO vehicle or
1 μg/ml SB (p38 inhibitor) for CEM cells or 2 μg/ml SB
for Molt-4 and RPMI 8226 cells before adding 1 μM
Dex. Cells were enumerated and sized, with viability de-
termined by Trypan blue exclusion assay, using a Vi-cell
automated counter (Beckman Coulter, Fullerton, CA).
For evaluation of acute demethylation, Molt-4 cells were
exposed to 100 nM AZA for 24 hours prior to adding
1 μM Dex.
Derivation of clones and analysis of Dex sensitivityciv
Preliminary dose-response experiments established the
optimal concentration of AZA for production of Dex
sensitivity. Consequently, CEM-C1-15, Molt-4, or RPMI
8226 cells were incubated for 48 hours in 100 nM AZA
or an equal volume of its DMSO vehicle for controls,
after which time the cells were pelleted by centrifugation
(Beckman Coulter, Allegra 6R table-top centrifuge) at
200 × g for 5 minutes at room temperature, their super-
natant medium aspirated, and resuspended in 10 mls of
sterile phosphate-buffered saline (PBS) (Cellgro). Cells
were pelleted as before, resuspended in fresh growth
medium without AZA, and allowed to recover for 5
days. The samples were cloned by serial dilution to sin-
gle cells in RPMI 1640 supplemented with 10% FBS and
an insulin-transferin-selenium supplement cocktail.
Cloning medium for Molt-4 and RPMI cells also con-
tained 10 mM Hepes and 1 mM sodium pyruvate. Ap-
proximately 1 month after cloning, cell populations from
each clone were grown to about 105 cells per ml and
evaluated for Dex sensitivity by exposure ± 1 μM Dex
for 96 hours. At that time, cells were counted and evalu-
ated for Trypan Blue dye exclusion, size and morphology
(Vi-cell, Beckman). Two calculations were performed:
1.% apoptosis in the residual whole-cell population = %
Trypan Blue positive cells in Dex-treated population
munus % TB positive cells in Vehicle-treated Control
population; and 2. “growth represson” = (100-% Trypan
Blue neg cells/total cells, Dex/Control).
Analysis of cell death
The Guidelines published in 2009 in Cell Death and Dif-
ferentiation were followed: “…investigators need tocombine at least two distinct methods,…and perform,
whenever possible, long-term survival assays…” [43]. Ac-
cordingly, cells were evaluated in 4 ways- by phase con-
trast light microscopy, by vital dye exclusion and cell
size- with on-screen visualization of cultures (Vi-cell,
Beckman), by flow cytometry, and by multiday cell cul-
tures following total and viable cells over time.
Clonogenicity
RPMI 8226 cells were incubated with 100 nM AZA or
DMSO vehicle for 40 hours before addition of ethanol
vehicle or 1 μM Dex for an additional 96 hours. Cells
were then counted and immediately serially diluted in
multi-well dishes to initial average densities of 1000,
100, 10, or single cells per well. After 2 weeks they were
evaluated by Trypan blue exclusion assay for wells with
live cells and viable cells per well enumerated.
Cytosine extension assay
The methylation state of cytosines within genomic DNA
was analyzed using a cytosine extension method [59].
Cellular genomic DNA was extracted from logarithmic-
ally growing CEM-C1-15, CEM-IV B9, RPMI 8226,
RPMI-II E6, or Molt-4 cells treated with DMSO vehicle
or 100 nM AZA for 48 hours using a Qiagen DNeasy
mini-prep kit (Qiagen, Valencia, CA). Residual RNA
contamination was eliminated by digestion with 400 μg
of RNase A. Purified DNA was quantified and 2 μg was
digested overnight at 37°C using 8 units of the
methylation-sensitive restriction enzyme Hpa II (New
England Biolabs, Ipswich, MA). Extension was per-
formed by combining 0.25 μg of digested DNA in the
presence of 3H deoxycytidine triphosphate (dCTP) (53.0
Ci/mmol, Perkin Elmer, Waltham, MA), 0.25 units of
TAQ polymerase (New England Biolabs), and buffer sup-
plied with the enzyme for 1 hour at 56°C. Samples were
subsequently placed on ice and duplicate 10 μl aliquots
were bound onto Whatman DE-81 ion exchange filter
papers (Whatman Inc., Florham Park, NJ) using a vac-
uum manifold. Filters were washed 3 times with 0.5 ml
room temperature PBS, air dried, submerged in 3 mls of
Scintiverse scintillation fluid (Fisher Scientific, Fair
Lawn, NJ), vigorously vortex mixed for 15 seconds,
allowed to recover for 1 hour, and evaluated using a
Beckman scintillation counter (Beckman Coulter).
Propidium iodide staining and flow cytometry
CEM-C7-14, CEM-C1-6, CEM-C1-15, CEM-IV B9,
RPMI 8226, and RPMI-II E6 cells were diluted to a start-
ing density of 5×104 viable cells/ml and treated with
ethanol vehicle (control) or 1 μM Dex for 96 hours.
Molt-4 cells were diluted to 5×104 viable cells/ml and
treated with ethanol/DMSO vehicle (control), 1 μM Dex
alone, or pre-treated for 24 hours with 100 nM AZA
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for an additional 72 hours. Cell nuclear suspensions
were prepared, stained by PI, and analyzed by flow cy-
tometry in the UTMB Cytometry Core Lab as described
[18].
Quantitative, real-time PCR of mRNA transcripts
TaqMan® real-time PCR assay and Taqman One-Step RT-
PCR reagents (Applied Biosystems, Foster City, CA) were
used to detect mRNA transcripts. The primers and Taqman
probes used for hGR transcripts (1A3, 1C and 1D), c-Myb
and PU.1 were described previously [52]. For measuring
PGC-1a mRNA transcripts, 5′-AGAGACAAATGCACCT
CCAAAAA-3′ (forward), 5′-6-FAM-AAGTCCCACACA-
CAGTCGCAGTCACAA-TAMRA-3′ (Taqman probe) and
5′-AAAGTTGTTGGTTTGGCTTGTAAGT -3′ (reverse)
were synthesized (Integrated DNA Technologies, Inc., San
Diego, CA). The RT-qPCR reactions were measured on an
ABI Prism 7900H Sequence Detection system (Applied
Biosystems) and the results were normalized by endogen-
ous 18S rRNA of each sample. The experiment was re-
peated and the results were pooled for statistical
significance analysis (paired-sample t-test). Less than 5%
(p < 0.05) of possible difference was considered significant.
Immunochemical analysis
Logarithmically growing CEM-C7-14, CEM-C1-6, CEM-
C1-15, and CEM-IV B9 cells were diluted to a starting



















Sequencing:with 100 nM Dex (GR blot), 1 μM Dex (p38 blot), or
ethanol/DMSO vehicle (control). Evaluation of GR
phospho-S211, total GR, phospho-p38, total p38, and
actin by immunoblot was carried out as previously de-
scribed [17,18].
GR transactivation assay
Logarithmically growing CEM-C1-6, CEM-C1-15, or
CEM-IV B9 cells were collected by centrifugation, washed
with 10 ml of sterile 37°C PBS and recollected. The cells
were resuspended to a density of 1×107 viable cells/ml in
serum-free 37°C RPMI 1640 containing 1.25% DMSO. Ali-
quots (400 μl) of the suspension were placed into 0.4 cm
gap electroporation cuvettes (Bio-Rad, Hercules, CA) con-
taining 15 μg of GRE-dependant mouse mammary tumor
virus (MMTV) luciferase reporter vector phh-Luc (ATCC)
prepared using a Qiagen maxi-prep kit (Qiagen). Cuvettes
were electroporated using 975 μF and 270 V with a Gene
Pulser II (Bio-Rad). Electroporated cells were diluted in
4 ml (per cuvette) of RPMI 1640 supplemented with 5%
FBS and 1.25% DMSO and recultured. Twenty-four hours
after electroporation, cellular debris was removed by filter-
ing through a 70 μm nylon cell strainer (BD Biosciences
(Falcon), Two Oak Park, Bedford, MA) and cells were pel-
leted, resuspended in fresh RPMI 1640 containing 5% FBS,
and viable cells were quantified by hemacytometer using
Trypan blue exclusion. The cultures were diluted to
2.5×105 viable cells/ml in RPMI 1640 supplemented with
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ment, and placed in a 48-well tissue culture plate (Costar,
Cambridge, MA). Twenty-four hours after Dex treatment,
cells were pelleted and washed with PBS. Luciferase activity
was evaluated by lysing cell pellets in reporter lysis buffer
(Promega, Madison, WI), 1 round of freeze-thaw at -80°C
to 37°C, and activation of enzymatic activity using luciferase
substrate (Promega). Relative light units (RLU) were read
using a Monolight luminometer (BD Biosciences). RLUs
were normalized to μg of protein in the cellular lysate
through use of a BCA protein assay (Pierce, Rockford, IL).
High Throughput DNA sequencing
Total DNA from cells of C1-15, C7-14, and post-
demethylation clone C1-15 IV B9 was fragmented by sonic-
ation into pieces of about 200 bp. DNA preparations were
obtained representing DNA enriched for non-methylated
or methylated by an immunoprecipitation procedure ac-
cording to manufacturer’s protocols. . These fractions were
sequenced in 36 bp fragments (reads) using an Illumina
GA IIx instrument, following the manufacturer’s protocols.
Quality assessment, trimming, and filtration of low quality
reads were performed using our Slim-Filter software appli-
cation [60]. The resulting high quality 31 bp reads were
mapped to the reference human genome, build 37.3, using
our in-house software. The ratios of experimental to theor-
etical reads at each position were computed to “normalize”
the results, allowing comparisons of samples. The relative
methylation status of all autosomes was determined, and
the coverage across the chromosomes was calculated using
a non-overlapping window size of 5000 bp. The raw se-
quencing data have been deposited as FASTQ files in SRA
data base, identifiable under PRJNA209577. For more spe-
cific data, please contact the Corresponding Author.
Pyrosequencing
Primers were designed using PyroMark Assay Design soft-
ware version 2.0 (Qiagen). Pyrosequencing was carried out
on PyroMark Q24 (Qiagen). Depending on the direction of
sequencing, one of the PCR primers was biotinylated at the
5-end. All primers used for amplification of the GR prox-
imal promoter are listed below in Table 3.
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